Skip to main content
Premium Trial:

Request an Annual Quote

Lawsuit against Isis over Kynamro Safety Report Dismissed

Premium

A lawsuit filed against Isis Pharmaceuticals for allegedly misleading shareholders over claims made about the company's cholesterol-lowering antisense drug Kynamro, which was the subject of a troubling regulatory review, has been dismissed, Gene Silencing News has learned.

The lawsuit, which was filed on behalf of Isis shareholders, claimed that Isis and its management made “materially false and misleading statements regarding the safety and efficacy of the product, as well as reportedly positive results from Kynamro’s clinical trials” (GSN 1/3/2013).

In October, the US Food and Drug Administration published a clinical briefing document noting the incidence of abnormal growths or neoplasms in some patients treated with the drug, which had been submitted as a treatment for homozygous familial hypercholesterolemia. The report also found that three patients treated with Kynamro had died during clinical testing.

On the FDA report, shares of Isis tumbled nearly 22 percent.

Despite the report, the FDA last month approved Kynamro for the treatment of homozygous familial hypercholesterolemia (GSN 1/31/2013). And now, the litigation has been dismissed.

According to a court filing, the plaintiff has voluntarily agreed to drop the suit.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.